AU2023221549A1 - Synthesis of bruton's tyrosine kinase inhibitors - Google Patents
Synthesis of bruton's tyrosine kinase inhibitors Download PDFInfo
- Publication number
- AU2023221549A1 AU2023221549A1 AU2023221549A AU2023221549A AU2023221549A1 AU 2023221549 A1 AU2023221549 A1 AU 2023221549A1 AU 2023221549 A AU2023221549 A AU 2023221549A AU 2023221549 A AU2023221549 A AU 2023221549A AU 2023221549 A1 AU2023221549 A1 AU 2023221549A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- hours
- solvent
- contacting
- base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Health & Medical Sciences (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Pyridine Compounds (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20220100151 | 2022-02-18 | ||
| GR20220100151 | 2022-02-18 | ||
| EP22167032 | 2022-04-06 | ||
| EP22167032.6 | 2022-04-06 | ||
| EP22178413.5 | 2022-06-10 | ||
| EP22178413 | 2022-06-10 | ||
| PCT/EP2023/054043 WO2023156599A1 (en) | 2022-02-18 | 2023-02-17 | Synthesis of bruton's tyrosine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2023221549A1 true AU2023221549A1 (en) | 2024-10-03 |
Family
ID=85227338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023221549A Pending AU2023221549A1 (en) | 2022-02-18 | 2023-02-17 | Synthesis of bruton's tyrosine kinase inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250163076A1 (https=) |
| EP (1) | EP4479405A1 (https=) |
| JP (1) | JP2025506671A (https=) |
| KR (1) | KR20240148351A (https=) |
| AU (1) | AU2023221549A1 (https=) |
| CA (1) | CA3252338A1 (https=) |
| CL (1) | CL2024002409A1 (https=) |
| CO (1) | CO2024011229A2 (https=) |
| IL (1) | IL314902A (https=) |
| JO (1) | JOP20240182A1 (https=) |
| MX (1) | MX2024010134A (https=) |
| PE (1) | PE20242069A1 (https=) |
| WO (1) | WO2023156599A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025262118A1 (en) * | 2024-06-20 | 2025-12-26 | Janssen Pharmaceutica Nv | Combination therapy using a malt1 inhibitor and a btk inhibitor |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3794B1 (ar) * | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون |
| WO2018103060A1 (en) * | 2016-12-09 | 2018-06-14 | Janssen Pharmaceutica Nv | Inhibitors of bruton's tyrosine kinase and methods of their use |
-
2023
- 2023-02-17 AU AU2023221549A patent/AU2023221549A1/en active Pending
- 2023-02-17 KR KR1020247027226A patent/KR20240148351A/ko active Pending
- 2023-02-17 EP EP23705025.7A patent/EP4479405A1/en active Pending
- 2023-02-17 WO PCT/EP2023/054043 patent/WO2023156599A1/en not_active Ceased
- 2023-02-17 MX MX2024010134A patent/MX2024010134A/es unknown
- 2023-02-17 JP JP2024547937A patent/JP2025506671A/ja active Pending
- 2023-02-17 IL IL314902A patent/IL314902A/en unknown
- 2023-02-17 PE PE2024001734A patent/PE20242069A1/es unknown
- 2023-02-17 US US18/838,678 patent/US20250163076A1/en active Pending
- 2023-02-17 CA CA3252338A patent/CA3252338A1/en active Pending
-
2024
- 2024-08-12 CL CL2024002409A patent/CL2024002409A1/es unknown
- 2024-08-14 JO JOJO/P/2024/0182A patent/JOP20240182A1/ar unknown
- 2024-08-20 CO CONC2024/0011229A patent/CO2024011229A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024010134A (es) | 2024-08-27 |
| CA3252338A1 (en) | 2023-08-24 |
| KR20240148351A (ko) | 2024-10-11 |
| EP4479405A1 (en) | 2024-12-25 |
| IL314902A (en) | 2024-10-01 |
| PE20242069A1 (es) | 2024-10-18 |
| JP2025506671A (ja) | 2025-03-13 |
| JOP20240182A1 (ar) | 2024-08-14 |
| CO2024011229A2 (es) | 2024-08-30 |
| US20250163076A1 (en) | 2025-05-22 |
| WO2023156599A1 (en) | 2023-08-24 |
| CL2024002409A1 (es) | 2025-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2587782T3 (es) | Síntesis de compuesto antivírico | |
| JP6692836B2 (ja) | Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物 | |
| JP7425724B2 (ja) | Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物及びその誘導体 | |
| EP3248980B1 (en) | Jak inhibitor | |
| WO2022266258A1 (en) | Compounds and methods for the targeted degradation of irak-4 | |
| JP7797486B2 (ja) | 新規なｒｈｏ関連タンパク質キナーゼ阻害剤の調製方法およびその調製方法における中間体 | |
| WO2025053850A1 (en) | Covalent kras-binding compounds for medical treatment | |
| TW201620894A (zh) | 作為rho激酶抑制劑的異喹啉磺醯衍生物 | |
| JP7840334B2 (ja) | 芳香族複素環式化合物、薬学的組成物、及びその使用 | |
| US20190152992A1 (en) | Benzodioxane derivatives and their pharmaceutical use | |
| WO2023156599A1 (en) | Synthesis of bruton's tyrosine kinase inhibitors | |
| US20220363680A1 (en) | Processes for the synthesis of valbenazine | |
| EP3681881B1 (en) | Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders | |
| BR112021001270A2 (pt) | piridopirimidinas como inibidores do receptor h4 da histamina | |
| AU2022221663A1 (en) | Pyrimidine compound as wee-1 inhibitor | |
| JP7068402B2 (ja) | チアゾール誘導体の製造方法 | |
| KR20170015339A (ko) | 혈액응고인자 Xa 억제제로서의 히드라진 화합물 | |
| WO2022049253A1 (en) | Substituted n-heteroaryl-n-pyridinylacetamides as p2x4 modulators | |
| AU2018393409A1 (en) | Tetrahydropyrrole compound, preparation method therefor, pharmaceutical composition containing same, and use thereof | |
| CN118715228A (zh) | 布鲁顿酪氨酸激酶抑制剂的合成 | |
| HK40111046A (zh) | 布鲁顿酪氨酸激酶抑制剂的合成 | |
| TW202508560A (zh) | 製備ｐ１３ｋ抑制劑之方法 | |
| KR20260052982A (ko) | Pi3k 억제제의 제조 방법 | |
| CN120787219A (zh) | 具有取代的戊二酰亚胺基异吲哚啉酮新颖骨架的化合物及其应用 | |
| JP2017149690A (ja) | トリアジノン化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ TRAN, NGOC DUC; XIOURAS, CHRISTOS; CLEATOR, EDWARD; MATON, WILLIAM MARC; RAMMELOO, THOMAS JOACHIM LANDEWALD; FERNANDES, PHILIPPE; BONGARTZ, JEAN-PIERRE A; CAO, DUY CHI TRUNG; HORWITZ, MATTHEW ALLAN; JUSSEAU, XAVIER JEAN-MARIE; LEMAIRE, SEBASTIEN FRANCOIS EMMANUEL AND SCHWEITZERCHAPUT, BERTRAND |